Reviewer's report

**Title:** Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies.

**Version:** 1  **Date:** 29 November 2013

**Reviewer:** Murat Inanc

**Reviewer's report:**

This commentary is on a recent paper on the manuscript: Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

Matthew Cawson, Stephen A Mitchell, Chris Knight, Henry Wildey, Dean Spurden, Alex Bird and Michelle E Orme

The authors correctly identified the deficiencies in the current state of economic analysis of new and expensive treatments. Most of the similar analysis in the literature were done by drug companies for regulatory purposes or these were supported by industry. This fact does not mean that the analysis itself had technical problems but the data itself was generally insufficient and was not generated for economic purposes. So the readers must be reminded that for these complex chronic diseases and highly sophisticated treatment strategies, these findings are extrapolations and there is no real head to head or long term comparison to reach a conclusion. I think the commentary written by Lubrano and Spadaro shows some of these caveats nicely and my advice is to accept it for publication.